USMJ PURA - North American Cannabis Holdings In Negotiations To Acquire Canadian Marijuana Dispensary
November 16 2017 - 9:21AM
InvestorsHub NewsWire
Dallas, TX -- November 16,
2017 -- InvestorsHub NewsWire -- North American Cannabis Holdings,
Inc. (USOTC:
USMJ) today announced the company is in negotiations to acquire
an established medical marijuana dispensary in Canada that has
applied for a recreational license in conjunction with the nationwide legalization of
recreational marijuana expected in Canada in July of
2018. The Canadian dispensary acquisition negotiations
are related to the announcement yesterday by North American
Cannabis Holdings sister company (both controlled by ACI
Conglomerated), Puration, Inc. (USOTC:
PURA):
Puration To Introduce Cannabis
Infused Beverages Into Legal $8 Billion Canadian Marijuana
Market
“Nationwide recreational marijuana legalization in Canada is a
major game changer within the cannabis sector,” Said Steven Rash,
CEO of both North American Cannabis Holdings, and ACI
Conglomerated. “Any cannabis company developing a sector
product or service offering should be looking to get into
Canada. Operating in the piecemeal legal U.S. market is
inherently inefficient, and such inefficiency is particularly
costly in a startup scenario. Developing new products within
the streamlined environment provided by nationwide legality is
ideal. Succeeding with this acquisition is a high
priority.”
USMJ - 44% Revenue Growth With 50% Gross
Margin
North American Cannabis Holdings recently released its annual
financial report for the fiscal year end 2017. The company
reported year to year revenue growth of 44% with revenue increasing
from $515,000 in 2016 to $742,000. The company reported a
gross margin of $408,000 reflecting a gross margin rate of over
50%.
Learn more about USMJ, its parent company, ACI, and ACI’s other
holdings to include PURA by visiting: http://www.aciconglomerated.com/
Disclaimer/Safe Harbor: This news release contains
forward-looking statements within the meaning of the Securities
Litigation Reform Act. The statements reflect the Company's current
views with respect to future events that involve risks and
uncertainties. Among others, these risks include the expectation
that any of the companies mentioned herein will achieve significant
sales, the failure to meet schedule or performance requirements of
the companies' contracts, the companies' liquidity position, the
companies' ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not occur.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat,
cure, or prevent any disease.
ACI, USMJ and PURA contact info:
Steven Rash
info@aciconglomerated.com
+1-800-861-1350
https://www.aciconglomerated.com/contact/
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Sep 2023 to Sep 2024